156 related articles for article (PubMed ID: 22297723)
1. Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease.
Ma P; Mali RS; Martin H; Ramdas B; Sims E; Kapur R
Leukemia; 2012 Jul; 26(7):1499-1506. PubMed ID: 22297723
[TBL] [Abstract][Full Text] [Related]
2. Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.
Mali RS; Ma P; Zeng LF; Martin H; Ramdas B; He Y; Sims E; Nabinger S; Ghosh J; Sharma N; Munugalavadla V; Chatterjee A; Li S; Sandusky G; Craig AW; Bunting KD; Feng GS; Chan RJ; Zhang ZY; Kapur R
Blood; 2012 Sep; 120(13):2669-78. PubMed ID: 22806893
[TBL] [Abstract][Full Text] [Related]
3. Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT.
Munugalavadla V; Sims EC; Chan RJ; Lenz SD; Kapur R
Exp Hematol; 2008 Mar; 36(3):301-8. PubMed ID: 18179858
[TBL] [Abstract][Full Text] [Related]
4. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
Bandi SR; Brandts C; Rensinghoff M; Grundler R; Tickenbrock L; Köhler G; Duyster J; Berdel WE; Müller-Tidow C; Serve H; Sargin B;
Blood; 2009 Nov; 114(19):4197-208. PubMed ID: 19734451
[TBL] [Abstract][Full Text] [Related]
5. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R
Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298
[TBL] [Abstract][Full Text] [Related]
6. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.
Bibi S; Arslanhan MD; Langenfeld F; Jeanningros S; Cerny-Reiterer S; Hadzijusufovic E; Tchertanov L; Moriggl R; Valent P; Arock M
Haematologica; 2014 Mar; 99(3):417-29. PubMed ID: 24598853
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation.
Agarwal S; Kazi JU; Rönnstrand L
J Biol Chem; 2013 Aug; 288(31):22460-8. PubMed ID: 23803604
[TBL] [Abstract][Full Text] [Related]
8. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
Grimwade LF; Happerfield L; Tristram C; McIntosh G; Rees M; Bench AJ; Boyd EM; Hall M; Quinn A; Piggott N; Scorer P; Scott MA; Erber WN
Br J Haematol; 2009 Nov; 147(4):495-506. PubMed ID: 19747364
[TBL] [Abstract][Full Text] [Related]
9. Lipid rafts are required for Kit survival and proliferation signals.
Jahn T; Leifheit E; Gooch S; Sindhu S; Weinberg K
Blood; 2007 Sep; 110(6):1739-47. PubMed ID: 17554062
[TBL] [Abstract][Full Text] [Related]
10. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation.
Hashimoto K; Matsumura I; Tsujimura T; Kim DK; Ogihara H; Ikeda H; Ueda S; Mizuki M; Sugahara H; Shibayama H; Kitamura Y; Kanakura Y
Blood; 2003 Feb; 101(3):1094-102. PubMed ID: 12393643
[TBL] [Abstract][Full Text] [Related]
11. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
Lindblad O; Kazi JU; Rönnstrand L; Sun J
Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
[TBL] [Abstract][Full Text] [Related]
12. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.
Chatterjee A; Ghosh J; Ramdas B; Mali RS; Martin H; Kobayashi M; Vemula S; Canela VH; Waskow ER; Visconte V; Tiu RV; Smith CC; Shah N; Bunting KD; Boswell HS; Liu Y; Chan RJ; Kapur R
Cell Rep; 2014 Nov; 9(4):1333-48. PubMed ID: 25456130
[TBL] [Abstract][Full Text] [Related]
14. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
[TBL] [Abstract][Full Text] [Related]
15. KIT associated intracellular tyrosines play an essential role in EpoR co-signaling.
Hong L; Ramdas B; Chen J; Harris C; Wojchowski DM; Kapur R
Cell Signal; 2008 Aug; 20(8):1513-20. PubMed ID: 18538998
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Aug; 120(9):1888-98. PubMed ID: 22837531
[TBL] [Abstract][Full Text] [Related]
17. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
Harir N; Boudot C; Friedbichler K; Sonneck K; Kondo R; Martin-Lannerée S; Kenner L; Kerenyi M; Yahiaoui S; Gouilleux-Gruart V; Gondry J; Bénit L; Dusanter-Fourt I; Lassoued K; Valent P; Moriggl R; Gouilleux F
Blood; 2008 Sep; 112(6):2463-73. PubMed ID: 18579792
[TBL] [Abstract][Full Text] [Related]
19. Expression of the adaptor protein Lnk in leukemia cells.
Gery S; Gueller S; Nowak V; Sohn J; Hofmann WK; Koeffler HP
Exp Hematol; 2009 May; 37(5):585-592.e2. PubMed ID: 19375649
[TBL] [Abstract][Full Text] [Related]
20. KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
Zhao L; Melenhorst JJ; Alemu L; Kirby M; Anderson S; Kench M; Hoogstraten-Miller S; Brinster L; Kamikubo Y; Gilliland DG; Liu PP
Blood; 2012 Feb; 119(6):1511-21. PubMed ID: 22160378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
